327 related articles for article (PubMed ID: 16226710)
21. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
22. Signal transduction by several KIT juxtamembrane domain mutations.
Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
[TBL] [Abstract][Full Text] [Related]
23. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
[TBL] [Abstract][Full Text] [Related]
24. A new twist in the transmembrane signaling tool-kit.
Lemmon MA; Ferguson KM
Cell; 2007 Jul; 130(2):213-5. PubMed ID: 17662934
[TBL] [Abstract][Full Text] [Related]
25. Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor.
Thömmes K; Lennartsson J; Carlberg M; Rönnstrand L
Biochem J; 1999 Jul; 341 ( Pt 1)(Pt 1):211-6. PubMed ID: 10377264
[TBL] [Abstract][Full Text] [Related]
26. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
27. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.
Reber L; Da Silva CA; Frossard N
Eur J Pharmacol; 2006 Mar; 533(1-3):327-40. PubMed ID: 16483568
[TBL] [Abstract][Full Text] [Related]
28. Interaction and functional cooperation between the serine/threonine kinase bone morphogenetic protein type II receptor with the tyrosine kinase stem cell factor receptor.
Hassel S; Yakymovych M; Hellman U; Rönnstrand L; Knaus P; Souchelnytskyi S
J Cell Physiol; 2006 Feb; 206(2):457-67. PubMed ID: 16155937
[TBL] [Abstract][Full Text] [Related]
29. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
[TBL] [Abstract][Full Text] [Related]
30. The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain.
Walter M; Lucet IS; Patel O; Broughton SE; Bamert R; Williams NK; Fantino E; Wilks AF; Rossjohn J
J Mol Biol; 2007 Mar; 367(3):839-47. PubMed ID: 17292918
[TBL] [Abstract][Full Text] [Related]
31. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
Seeliger MA; Nagar B; Frank F; Cao X; Henderson MN; Kuriyan J
Structure; 2007 Mar; 15(3):299-311. PubMed ID: 17355866
[TBL] [Abstract][Full Text] [Related]
32. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
[TBL] [Abstract][Full Text] [Related]
33. Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain.
Jahn T; Seipel P; Coutinho S; Urschel S; Schwarz K; Miething C; Serve H; Peschel C; Duyster J
Oncogene; 2002 Jul; 21(29):4508-20. PubMed ID: 12085229
[TBL] [Abstract][Full Text] [Related]
34. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
Mol CD; Fabbro D; Hosfield DJ
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):639-48. PubMed ID: 15503866
[TBL] [Abstract][Full Text] [Related]
35. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
36. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
37. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
38. Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages.
Kimura Y; Jones N; Klüppel M; Hirashima M; Tachibana K; Cohn JB; Wrana JL; Pawson T; Bernstein A
Proc Natl Acad Sci U S A; 2004 Apr; 101(16):6015-20. PubMed ID: 15067126
[TBL] [Abstract][Full Text] [Related]
39. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.
Isozaki K; Terris B; Belghiti J; Schiffmann S; Hirota S; Vanderwinden JM
Am J Pathol; 2000 Nov; 157(5):1581-5. PubMed ID: 11073817
[TBL] [Abstract][Full Text] [Related]
40. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
